Choice of antihyprtensive therapy at varios stages of metabolically associated lever disease

Abstract

Metabolic dysfunction associated steatatotic liver disease (MASLD) and hypertension are two chronic progressive diseases that require a comprehensive approach. The article discusses approaches to the appointment of hypotensive and hypolipidemic therapy in patients with MASLD, depending on the stage of the disease.